Journal of the American Academy of Child & Adolescent Psychiatry
Volume 48, Issue 5 , Pages 511-518 , May 2009

Clinical Responses to Atomoxetine in Attention-Deficit/Hyperactivity Disorder: The Integrated Data Exploratory Analysis (IDEA) Study

,Accepted 8 January 2009.

References 

  1. Biederman J , Spencer TJ , Newcorn JH , et al.   Effect of comorbid symptoms of oppositional defiant disorder on responses to atomoxetine in children with ADHD: a meta-analysis of controlled clinical trial data . Psychopharmacology (Berl) . 2007;190:31–41
  2. Kelsey DK , Sumner CR , Casat CD , et al.   Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial . Pediatrics . 2004;14:e1–e8
  3. Kratochvil CJ , Heiligenstein JH , Dittmann R , et al.   Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial . J Am Acad Child Adolesc Psychiatry . 2002;41:776–784
  4. Kratochvil CJ , Wilens TE , Greenhill LL , et al.   Effects of long-term atomoxetine treatment for young children with attention-deficit/hyperactivity disorder . J Am Acad Child Adolesc Psychiatry . 2006;45:919–927
  5. Kratochvil CJ , Vaughan BS , Mayfield-Jorgensen ML , et al.   A pilot study of atomoxetine in young children with attention-deficit/hyperactivity disorder . J Child Adolesc Psychopharmacol . 2007;17:175–185
  6. Michelson D , Faries D , Wernicke J , et al.   Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study . Pediatrics . 2001;108:e83
  7. Michelson D , Allen AJ , Busner J , et al.   Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study . Am J Psychiatry . 2002;159:1896–1901
  8. Spencer T , Heiligenstein JH , Biederman J , et al.   Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder . J Clin Psychiatry . 2002;63:1140–1147
  9. McGough J , McCracken J , Swanson J , et al.   Pharmacogenetics of methylphenidate response in preschoolers with ADHD . J Am Acad Child Adolesc Psychiatry . 2006;45:1314–1322
  10. Michelson D , Read HA , Ruff DD , Witcher J , Zhang S , McCracken J . CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD . J Am Acad Child Adolesc Psychiatry . 2007;46:242–251
  11. Abikoff H , Hechtman L , Klein RG , et al.   Symptomatic improvement in children with ADHD treated with long-term methylphenidate and multimodal psychosocial treatment . J Am Acad Child Adolesc Psychiatry . 2004;43:802–811
  12. Rapport MD , Denney C , DuPaul GJ , Gardner MJ . Attention deficit disorder and methylphenidate: normalization rates, clinical effectiveness, and response prediction in 76 children . J Am Acad Child Adolesc Psychiatry . 1994;33:882–893
  13. Stein MA , Sarampote CS , Waldman ID , et al.   A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder . Pediatrics . 2003;112:e404
  14. Swanson JM , Kraemer HC , Hinshaw SP , et al.   Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment . J Am Child Adolesc Psychiatry . 2001;40:168–179
  15. Hinshaw SP . Moderators and mediators of treatment outcome for youth with ADHD: understanding for whom and how interventions work . J Pediatr Psychol . 2007;32:664–675
  16. March JS , Swanson JM , Arnold LE , et al.   Anxiety as a predictor and outcome variable in the multimodal treatment study of children with ADHD (MTA) . J Abnorm Child Psychol . 2000;28:527–541
  17. Rieppi R , Greenhill LL , Ford RE , et al.   Socioeconomic status as a moderator of ADHD treatment outcomes . J Am Acad Child Adolesc Psychiatry . 2002;41:269–277
  18. Owens EB , Hinshaw SP , Kraemer HC , et al.   Which treatment for whom for ADHD? Moderators of treatment response in the MTA . J Consult Clin Psychol . 2003;71:540–552
  19. Greenhill LL , Newcorn JH , Gao H , Feldman PD . Effect of two different methods of initiating atomoxetine on the adverse event profile of atomoxetine . J Am Acad Child Adolesc Psychiatry . 2007;46:566–572
  20. Newcorn J, Kratochvil C, Allen AJ et al. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response [published online ahead of print February 15, 2008]. Am J Psychiatry. doi:10.1176/appi.ajp.2007.05091676.
  21. Sangal RB , Owens J , Allen AJ , Sutton V , Schuh K , Kelsey D . Effects of atomoxetine and methylphenidate on sleep in children with ADHD . Sleep . 2006;29:1573–1585
  22. Carlson GA , Dunn D , Kelsey D , et al.   A pilot study for augmenting atomoxetine with methylphenidate: safety of concomitant therapy in children with attention-deficit/hyperactivity disorder . Child Adolesc Psychiatry Ment Health . 2007;1:10
  23. Kelsey D, Sutton V, Lewis D, Schuh K, Sumner C, Quintana H. Morning-dosed versus evening-dosed atomoxetine for treating ADHD in children. Presented at Annual Meeting of the American Psychiatric Association; Psychosomatic Medicine: Integrating Psychiatry and Medicine; Atlanta, GA; May 21–26, 2005.
  24. Faries DE , Yalcin I , Harder D , Heiligenstein JH . Validation of the ADHD rating scale as a clinician administered and scored instrument . J Atten Disord . 2001;5:39–47
  25. American Psychiatric Association  . Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Revised (DSM-IV-R) . Washington: American Psychiatric Association; 2000;
  26. Farrar JT , Young JP , LaMoreaux L , Werth JL , Poole RM . Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale . Pain . 2001;94:149–158
  27. Gao H, Zhao Y, Levine L, Allen AJ. Determining cut-points for clinically meaningful improvement: a ROC approach. Presented at the 53rd Annual Meeting of the American Academy of Child and Adolescent Psychiatry; San Diego; Oct. 24–29, 2006.
  28. Chen S , Chou W-H , Blouin RA , et al.   The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: screening costs and influence on clinical outcomes in psychiatry . Clin Pharmacol Ther . 1996;60:522–534
  29. Newcorn JH , Michelson D , Kratochvil CJ , Allen AJ , Ruff DD , Moore RJ . Low-dose atomoxetine for maintenance treatment of attention-deficit/hyperactivity disorder . Pediatrics . 2006;118:E1701–E1706
  30. Dickson RA, Jackiewicz G, Khattak S et al. Change in ADHD symptoms and functional outcomes in Canadian children during 3 months of atomoxetine treatment. Presented at: World Psychiatric Association International Congress 2007; November 28 to December 2, 2007; Melbourne, Victoria, Australia.
  31. Montoya A, Escobar R, Gilalberto I et al. Continued improvement in newly diagnosed children and adolescents with attention-deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled trial of atomoxetine. Presented at: 13th International Congress of the European Society for Child and Adolescent Psychiatry (ESCAP); August 25–29, 2007; Florence, Italy.
  32. Quitkin FM , McGrath PJ , Stewart JW , et al.   Chronological milestones to guide drug change. When should clinicians switch antidepressants? . Arch Gen Psychiatry . 1996;53:785–792
  33. Gordon E , Liddell BJ , Brown KJ , et al.   Integrating objective gene-brain-behavior markers of psychiatric disorders . J Integr Neurosci . 2007;6:1–34
  34. Elia J , Welsh PA , Gullotta CS , Rapoport JL . Classroom academic performance: improvement with both methylphenidate and dextroam-phetamine in ADHD boys . J Child Psychol Psychiatry . 1993;34:785–804
  35. Arnsten AF , Scahill L , Findling RL . Alpha2-Adrenergic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: emerging concepts from new data . J Child Adolesc Psychopharmacol . 2007;17:393–406
  36. Rapoport JL , Inoff-Germain G . Responses to methylphenidate in attention-deficit/hyperactivity disorder and normal children: update 2002 . J Atten Disord . 2002;6:S57–S60

 Funding for this research was provided by Eli Lilly and Company.The authors thank Stephen W. Gutkin of Rete Biomedical Communications for assistance in manuscript preparation.Clinical trials registration information—Evaluation of Continuous Symptom Treatment of ADHD: A Placebo-Controlled Double-Blind Assessment of Morning-Dosed or Evening-Dosed Strattera. URL: http://www.clinicaltrials.gov. Unique identifier: NCT00486122. Results of the other studies analyzed in the Integrated Data Exploratory Analysis study are posted at www.clinicalstudyresults.org, ID numbers 5670, 7972, 2746, 1585, 1586, and 3468, and www.lillytrials.com.

PII: S0890-8567(09)60068-X

doi: 10.1097/CHI.0b013e31819c55b2

Journal of the American Academy of Child & Adolescent Psychiatry
Volume 48, Issue 5 , Pages 511-518 , May 2009

Article Tools

* Image Usage & Resolution